The drug discovery revolution is real but radically overstated, the health chatbots are a documented hazard, and the diseases that matter most remain stubbornly unsolved. At Novartis, sometime in late 2025, a team of researchers working on Huntington’s…
The case for AI prescription renewals is real. So is the case against trusting a state sandbox to catch the risks. In January, a security research firm called Mindgard sat down with a chatbot. The chatbot had been built by Doctronic, a health technolog…
The Berkeley biotech is backing a Nature-published approach that recreates the embryonic environment where blood stem cells first form, rather than reprogramming aged cells chemically or genetically. Its lead programme targets bone marrow transplant in…
The French-Belgian medtech uses a portable headset to capture up to 800 infrared images per eye per second, extracting oculomotor biomarkers that can indicate Parkinson’s, Alzheimer’s, and multiple sclerosis years before clinical symptoms appear. It re…
Anthropic has acquired Coefficient Bio, a stealth biotech AI startup founded barely eight months ago, in an all-stock deal worth just over $400 million. The acquisition brings a team of fewer than 10 people, nearly all former Genentech computational bi…
The Paris techbio company screens microbial genomes to find molecules that evolution spent three billion years producing, and claims to have characterised more novel small molecules in 2025 than the rest of the field combined. Alven and Daphni co-led t…
The Copenhagen-based health AI company built Symphony on peer-reviewed research from the largest medical coding study of its kind, treating coding as a reasoning task rather than a labelling problem. It’s available via API now. Medical coding, the proc…
The all-female-founded company, backed by Oura Health co-founders and Business Finland, uses brainwave entrainment to support focus, sleep, and recovery via background audio. Its new Sleep Headband targets secure environments where phones are banned. A…
The Ontario startup combines AI with trained human professionals to help patients navigate PCOS, endometriosis, fertility, and perimenopause, the conditions with the longest diagnostic delays and most fragmented care in the system. Graphite Ventures le…
The Dutch biotech’s SureTACs platform targets membrane proteins that have long eluded conventional drug discovery by engineering them out of existence rather than blocking them. Biovance Capital joins as new co-lead alongside Kurma Partners in a final …